Rapamycin for Longevity: The mTOR Inhibitor That Extended Lifespan in Every Species Tested

What Rapamycin Is#

Rapamycin (sirolimus) is a macrolide compound originally isolated from a soil bacterium (Streptomyces hygroscopicus) found on Easter Island (Rapa Nui — hence the name) in the 1970s. It was initially developed as an antifungal, then as an immunosuppressant for organ transplant recipients, and later as an anti-cancer agent.

Its longevity properties were discovered largely by accident: researchers studying rapamycin-treated animals kept noticing they lived longer than controls.

FDA-approved uses:

• Prevention of organ transplant rejection
• Treatment of certain cancers (renal cell carcinoma, breast cancer, some lymphomas)
• Tuberous sclerosis complex

Longevity use: Off-label, at much lower and intermittent doses than therapeutic use. Requires a physician prescription.

---

The Mechanism: mTOR Inhibition#

Rapamycin works by inhibiting mTOR (mechanistic target of rapamycin) — one of the most important nutrient-sensing kinases in biology.

mTOR integrates signals from:

• Amino acids (particularly leucine)
• Growth factors (insulin, IGF-1)
• Energy status (AMP:ATP ratio)
• Oxygen availability

When nutrients are abundant, mTOR is active — it promotes cell growth, protein synthesis, and proliferation. When nutrients are scarce, mTOR is suppressed — it activates autophagy, reduces protein synthesis, and shifts the cell into maintenance mode.

The ageing connection: Chronically elevated mTOR activity (from continuous nutrient surplus — the modern Western dietary pattern) drives accelerated ageing by:

• Suppressing autophagy (cellular waste accumulates)
• Promoting cellular senescence
• Impeding stem cell maintenance
• Driving cancer cell proliferation
• Accelerating epigenetic ageing

mTOR inhibition by rapamycin mimics the effect of caloric restriction at the molecular level — but without requiring food deprivation.

---

The Landmark Lifespan Data#

The ITP Studies (Intervention Testing Program)#

The National Institute on Aging's Intervention Testing Program (ITP) is the most rigorous longevity drug testing programme in existence. Compounds are tested at three independent testing sites simultaneously — if results are consistent across sites, the finding is considered highly reliable.

Rapamycin in ITP (Harrison et al., 2009, Nature):

• Rapamycin extended median lifespan in mice by 14% in females and 9% in males
• The most remarkable aspect: Treatment began at 20 months of age (equivalent to approximately age 60 in humans) — yet still produced significant lifespan extension
• This was the first demonstration that a drug could extend mammalian lifespan when treatment began in late life — suggesting the ageing process itself was being slowed, not simply preventing early disease

Subsequent ITP studies:

• Multiple replication studies confirm the lifespan extension
• Dose-response: higher doses produce greater extension (within the range tested)
• Combination with other compounds (metformin, acarbose) may produce additive effects

Extension to Other Species#

Rapamycin (or mTOR inhibition more broadly) extends lifespan in:

• Yeast
• C. elegans (worms)
• Drosophila (fruit flies)
• Mice (multiple independent studies)

The consistency across evolutionarily distant species — each with independent mTOR biology that nonetheless responds to inhibition in the same direction — is unusually compelling evidence for a conserved longevity mechanism.

---

Human Evidence#

The human evidence for rapamycin as a longevity drug is limited but growing:

Reboot Health Studies (Joan Mannick, Novartis)#

The only human trials specifically designed to test rapamycin's immune-rejuvenating effects in older adults.

Mannick et al. (2014, Science Translational Medicine): 218 older adults randomised to low-dose everolimus (a rapamycin analogue) or placebo for 6 weeks. At doses producing partial (not complete) mTOR inhibition:

• Improved immune response to influenza vaccination by 20% vs placebo
• Improved immune function markers
• Not the side effect profile expected from transplant-dose immunosuppression

Follow-up trial (2018): Low-dose rapalog improved immune function and reduced incidence of respiratory tract infections over a 12-month follow-up.

These trials established that low-dose, intermittent rapamycin does not produce clinically significant immunosuppression in older adults — contrary to the primary safety concern.

Observational Human Data#

No randomised lifespan trial in humans exists (the endpoint is impossible on the trial timescale). The available human evidence:

• Organ transplant patients on therapeutic-dose rapamycin (much higher doses than longevity protocols) show mixed outcomes depending on underlying disease and dose
• Retrospective analysis of transplant recipients on mTOR inhibitors vs calcineurin inhibitors: lower cancer incidence with mTOR inhibitors (consistent with the anti-tumour mechanism)

Ongoing Human Research#

Multiple groups are conducting human trials of rapamycin for longevity applications:

• PEARL trial (Dog Aging Project): Rapamycin in companion dogs — perhaps the best near-term human surrogate given dogs' shared environment with their owners
• Rapalong trial: Human trial of intermittent low-dose rapamycin — results awaited
• Multiple physician-led observational cohorts of healthy adults taking rapamycin off-label

---

The Dosing Protocol Used in Longevity Medicine#

The therapeutic immunosuppressant dose (for organ transplant) is daily rapamycin at blood trough levels of 5–15 ng/mL. This is the dose that produces the side effects feared in mainstream medicine.

The longevity protocol is radically different:

Pioneered by physicians including Peter Attia, Alan Green (who has treated over 1,000 patients), and others:

Intermittent low-dose protocol:

• 2–6mg once per week (most common: 5mg/week)
• Taken as a single weekly dose rather than daily
• Blood levels fluctuate dramatically — mTOR is inhibited for a period, then recovers

Rationale for intermittent dosing:

• mTOR inhibition requires time off to allow the beneficial cellular maintenance processes (autophagy, senescence clearance) to complete and then reset
• Intermittent dosing appears to capture the longevity benefit while avoiding the sustained immunosuppression of daily dosing
• Some evidence that intermittent mTOR inhibition is actually more effective for autophagy induction than continuous inhibition

---

The Side Effect Reality#

Rapamycin at transplant doses (daily, high) produces:

• Significant immunosuppression (infection risk)
• Impaired wound healing
• Metabolic side effects (elevated triglycerides, glucose impairment)
• Mouth sores (mucositis)
• Pulmonary toxicity (rare)

At weekly low doses (2–6mg/week):

• Mouth sores: ~20% of users (usually mild and transient; toothpaste avoidance in first day post-dose helps)
• Mild immune effects: subclinical; does not appear to increase clinical infection rates in healthy adults
• Metabolic effects: monitor triglycerides and glucose; usually minimal at low doses
• Wound healing: take a break from rapamycin 2–3 weeks before any planned surgery

Contraindications:

• Active infection
• Active malignancy being treated with cytotoxic chemotherapy
• Pregnancy or trying to conceive
• Significant immunodeficiency
• Recent surgery or upcoming surgery within 4 weeks

---

Finding a Prescribing Physician#

Rapamycin requires a prescription. Finding a physician who will prescribe off-label for longevity in a healthy patient is the primary access challenge.

Physicians who prescribe rapamycin for longevity:

• Longevity medicine physicians (Peter Attia's model — but individual access is limited)
• Alan Green (agingdoc.com) — one of the most prolific rapamycin prescribers in the US; offers telemedicine
• AgelessRx — telemedicine platform with physicians experienced in off-label longevity prescribing
• Many functional medicine physicians with longevity training

What to bring to the conversation:

• Baseline bloodwork (CBC, metabolic panel, lipids, HbA1c)
• Knowledge of the ITP data and Mannick trials
• Clear understanding that you want intermittent low-dose (not daily high-dose) and are aware of the experimental nature

---

Rapamycin vs Other mTOR Modulators#

Berberine and metformin: Both inhibit mTOR indirectly (via AMPK activation). Weaker effect than rapamycin on mTOR but available OTC (berberine) or by standard prescription (metformin). Good first-line approach.

Dietary mTOR modulation: Protein restriction and intermittent fasting suppress mTOR. Effective but requires ongoing dietary restriction.

Rapalogs (everolimus, temsirolimus): Second-generation mTOR inhibitors with slightly different pharmacokinetics. Everolimus is the compound tested in the Mannick human trials.

---

The Honest Bottom Line#

Rapamycin is the most compelling existing drug for longevity based on the animal data. The ITP findings — reproducible lifespan extension in late-started treatment — have no equivalent in the longevity drug literature.

The human evidence is limited because no human lifespan RCT exists or can practically exist. The Mannick immune trials provide the best available human data suggesting low-dose intermittent rapamycin is safe and biologically active in the direction desired.

For serious longevity medicine practitioners, rapamycin is at the frontier of reasonable pharmacological intervention — with appropriate monitoring and physician oversight. For most people, the fundamentals (exercise, sleep, nutrition, stress) should be optimised before considering rapamycin. But for those who have done the work and want to explore the frontier, rapamycin is where the most credible data currently points.